Nabriva Therapeutics PLC (NBRV)
| Market Cap | 12.80M |
| Revenue (ttm) | 35.33M |
| Net Income (ttm) | -46.61M |
| Shares Out | 66.54M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 418,028 |
| Open | 0.205 |
| Previous Close | 0.203 |
| Day's Range | 0.192 - 0.212 |
| 52-Week Range | 0.156 - 1.400 |
| Beta | 1.48 |
| Analysts | Buy |
| Price Target | 2.04 (+960.3%) |
| Earnings Date | Aug 3, 2022 |
About NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well a... [Read more...]
Financial Performance
In 2021, NBRV's revenue was $28.90 million, an increase of 474.80% compared to the previous year's $5.03 million. Losses were -$49.45 million, -28.83% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for NBRV stock is "Buy." The 12-month stock price forecast is 2.04, which is an increase of 960.29% from the latest price.
News
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cys...
- Topline Data Expected First Quarter 2023 - - Topline Data Expected First Quarter 2023 -
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
-Net Product Sales of $8.7M Grew 25% versus Q2 2021-
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agent...
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026-
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the...
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innova...
Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with...
DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...
Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth-
Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022
— Meeting to Reconvene on March 24, 2022 —
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
— Meeting to Reconvene on January 18, 2022 —
Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021
-SIVEXTRO ® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022-
Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021
— Meeting to Reconvene on January 14, 2022 — — Meeting to Reconvene on January 14, 2022 —
Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
Nabriva Therapeutics AG (NBRV) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre...
Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
Down 25.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)
The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre...
Nabriva Therapeutics (NBRV) Sees Hammer Chart Pattern: Time to Buy?
Nabriva Therapeutics (NBRV) has been struggling lately, but the selling pressure may be coming to an end soon.
Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack
10-count oral pack – or ‘X' pack allows for improved access and the opportunity to further expand retail availability 10-count oral pack – or ‘X' pack allows for improved access and the opportunity to f...
Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
-Revenues of $8.9 million increased 8% sequentially versus Q2 2021-
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...
Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021
DUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...